Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Clinical Trial Evaluating the Incidence of Upper Gastrointestinal Mucosal Damage Following Administration of Either PL3100 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated GI Damage

NCT01139190 is registered in ClinicalTrials.gov with PLx Pharma as lead sponsor.

NCT NCT01139190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01139190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Clinical Trial Evaluating the Incidence of Upper Gastrointestinal Mucosal Damage Following Administration of Either PL3100 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated GI Damage
Lead sponsor
PLx Pharma
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2010
Completion date
December 31, 2010
Enrollment
77 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

erosion, gastroduodenal ulcerations